Coronavirus company news summary – Gilead receives more emergency use authorisations for remdesivir – BerGenBio doses first participants in the UK’s ACCORD trial

Allie Nawrat 3 June 2020 (Last Updated June 3rd, 2020 08:58)

Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm EpiVax to advance a Covid-19 vaccine candidate based on Intravacc’s Outer Membrane Vesicles (OMV) platform. The aim is for the vaccine to produce a safe and effective T-cell response against SARS-CoV-2 and other related coronaviruses.

Gilead Sciences’ antiviral drug remdesivir has secured emergency use authorisations in South Korea and India for the potential treatment of Covid-19. The drug already received emergency use approval in the US, as well as approval from the Japanese regulatory authorities.

Norway-based BerGenBio has started dosing participants in the Phase II Accord Trial of bemcentinib for the treatment of hospitalised patients with Covid-19. Supported by the UK Government, ACCORD is designed to assess drug candidates in early stage trials and advance them into the country's large-scale Covid-19 studies.

Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development in the US have expanded their partnership with Infectious Disease Research Institute (IDRI) to accelerate the development and testing of a Covid-19 vaccine candidate. The partners will work on manufacturing and filling of vials to advance the product into Phase I studies.